Metabolic · Placeholder catalog data
GLP-1 (S)
A long-acting analog of human glucagon-like peptide-1 with extensive published literature across glycemic, weight, and cardiovascular research endpoints.
130 credits
Paid from your credit pool at checkout. Bulk quantities discount automatically.
Available variants
Pricing and fulfillment information is placeholder data.
| Amount | SKU | Credits | MSRP | Availability | Margin estimate |
|---|---|---|---|---|---|
| 5 mg | PTS-SEM-5 | 26 credits | $69 | Ready | 62% estimate |
| 10 mg | PTS-SEM-10 | 32 credits | $129 | Ready | 75% estimate |
| 20 mg | PTS-SEM-20 | 38 credits | $179 | Ready | 79% estimate |
| 30 mg | PTS-SEM-30 | 51 credits | $249 | Ready | 80% estimate |
Margin estimate treats 1 credit as $1 and compares estimated wholesale credit cost with placeholder MSRP. It excludes shipping, taxes, and other costs.
Buy more, save more
Quantity breaks apply per line item and are deducted automatically at checkout.
| Quantity per line | Discount | Example (5 mg unit) |
|---|---|---|
| 10+ units | 5% off | 10 × 26 credits → 247 credits |
| 25+ units | 10% off | 25 × 26 credits → 585 credits |
| 50+ units | 15% off | 50 × 26 credits → 1,105 credits |
| 100+ units | 20% off | 100 × 26 credits → 2,080 credits |
Specifications
- CAS
- 910463-68-2
- Formula
- C187H291N45O59
- Molecular weight
- 4113.58 g/mol
- Sequence
- HAEGTFTSDVSSYLEGQAAK(γE-γE-C18 diacid)EFIAWLVRGRG
- Purity
- ≥99%
- Appearance
- White lyophilized powder
- Storage
- Store lyophilized at 2–8 °C, protected from light and moisture
Quality record
COA status
COA listedLot PTS-SEM-2607
Placeholder reference. Verify the active lot before ordering.
Research background
Semaglutide is a long-acting analog of human GLP-1 in which position 8 is modified to resist DPP-4 degradation and a C18 fatty diacid linker enables reversible albumin binding for extended half-life. The molecule is approved as Ozempic®, Wegovy®, and Rybelsus® for glycemic and weight endpoints.
A large body of clinical and preclinical literature has investigated Semaglutide's actions at the GLP-1 receptor across islet cell function, gastric emptying, central appetite regulation, and cardiovascular outcomes.
Supplied exclusively as a laboratory reference standard for research investigating the GLP-1 axis. Not supplied for therapeutic use.
Mechanism: Literature describes Semaglutide as a GLP-1 receptor agonist with actions on pancreatic β-cells, delayed gastric emptying, and hypothalamic appetite circuits.
Research use only
For research use only. Not for human or veterinary use.